Last reviewed · How we verify
HPP2104-1
HPP2104-1 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.
HPP2104-1 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | HPP2104-1 |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
HPP2104-1 activates glucagon-like peptide-1 (GLP-1) receptors on pancreatic beta cells and alpha cells, stimulating glucose-dependent insulin secretion while suppressing glucagon secretion. The extended half-life formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists, improving patient compliance while maintaining sustained glycemic control.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Hypoglycemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HPP2104-1 CI brief — competitive landscape report
- HPP2104-1 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI